Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 188-193

  Zhuang, Junling ^a   Da, Yi ^a   Li, Hui ^a   Han, Bing ^a   Wan, Xia ^b   Zhu, Tienan ^a   Chen, Miao ^a   Duan, Minghui ^a   Xu, Ying ^a   Zhao, Yongqiang ^a   Shen, Ti ^a   Wua, Yongji ^a   Zhou, Daobin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Cytogenetic; Lactate dehydrogenase; Multiple myeloma; Prognosis; Risk factors; Ultra high risk

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART ARRHYTHMIA; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; INFECTION; INTERNATIONAL STAGING SYSTEM; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; CAUSE OF DEATH; CHROMOSOME ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84892540170     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.010     Document Type: Article

References (44)

1. Harousseau J.L., Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009, 360:2645-2654.
2. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
3. Avet-Loiseau H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program 2010, 2010:489-493.
4. Kapoor P., Rajkumar S.V. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol 2011, 94:310-320.
5. San Miguel J.F., Mateos M.V., Ocio E., Garcia-Sanz R. Multiple myeloma: treatment evolution. Hematology 2012, 17(Suppl 1):S3-S6.
6. Rajkumar S.V. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:78-88.
7. Munshi N.C., Anderson K.C., Bergsagel P.L., Shaughnessy J., Palumbo A., Durie B., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
8. Kapoor P., Fonseca R., Rajkumar S.V., Sinha S., Gertz M.A., Stewart A.K., et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapy. Mayo Clin Proc 2010, 85:532-537.
9. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Blade J., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
10. Nemec P., Zemanova Z., Kuglik P., Michalova K., Tajtlova J., Kaisarova P., et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012, 53:920-927.
11. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevieve F., Zandecki M., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001, 97:1566-1571.
12. Shaughnessy J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
13. Mulligan G., Mitsiades C., Bryant B., Zhan F., Chng W.J., Roels S., et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109:3177-3188.
14. Decaux O., Lode L., Magrangeas F., Charbonnel C., Gouraud W., Jezequel P., et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008, 26:4798-4805.
15. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., et al. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
16. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
17. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F., Offord J.R., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369.
18. Raja K.R., Kovarova L., Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010, 149:334-351.
19. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
20. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
21. Dimopoulos M.A., Richardson P.G., Schlag R., Khuageva N.K., Shpilberg O., Kastritis E., et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27:6086-6093.
22. Ludwig H., Adam Z., Hajek R., Greil R., Tothova E., Keil F., et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010, 28:4635-4641.
23. Gkotzamanidou M., Kastritis E., Gavriatopoulou M.R., Nikitas N., Gika D., Mparmparousi D., et al. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk 2011, 11:409-413.
24. Neben K., Lokhorst H.M., Jauch A., Bertsch U., Hielscher T., van der Holt B., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
25. Boyd K.D., Ross F.M., Chiecchio L., Dagrada G.P., Konn Z.J., Tapper W.J., et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012, 26:349-355.
26. Dispenzieri A., Rajkumar S.V., Gertz M.A., Fonseca R., Lacy M.Q., Bergsagel P.L., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341.
27. Neben K., Jauch A., Bertsch U., Heiss C., Hielscher T., Seckinger A., et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010, 95:1150-1157.
28. Klein U., Jauch A., Hielscher T., Hillengass J., Raab M.S., Seckinger A., et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011, 117:2136-2144.
29. Hanamura I., Stewart J.P., Huang Y., Zhan F., Santra M., Sawyer J.R., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006, 108:1724-1732.
30. Treon S.P., Maimonis P., Bua D., Young G., Raje N., Mollick J., et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000, 96:3147-3153.
31. Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004, 165:71-81.
32. Zhan F., Colla S., Wu X., Chen B., Stewart J.P., Kuehl W.M., et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007, 109:4995-5001.
33. Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A.T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993, 81:128-135.
34. Drach J., Ackermann J., Fritz E., Kromer E., Schuster R., Gisslinger H., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998, 92:802-809.
35. Waheed S., Shaughnessy J.D., van Rhee F., Alsayed Y., Nair B., Anaissie E., et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer 2011, 117:1001-1009.
36. Landau H., Pandit-Taskar N., Hassoun H., Cohen A., Lesokhin A., Lendvai N., et al. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leuk Lymphoma 2012, 53:275-281.
37. Jagannath S., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
38. Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin-Charbonnel C., Caillot D., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
39. Reece D., Song K.W., Fu T., Roland B., Chang H., Horsman D.E., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114:522-525.
40. Paiva B., Vidriales M.B., Cervero J., Mateo G., Perez J.J., Montalban M.A., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
41. Chen S., Li Y., Zhang P., Zhai Y., Sun W., Su L. A clinical analysis of 798 cases of M protein positive patients. Zhonghua Nei Ke Za Zhi 2001, 40:398-400.
42. Zhu J.Z., Kuo T.T., Wang H.R. Analysis of 128 cases of multiple myeloma and 31 cases of monoclonal gammapathies of undetermined significance. Zhonghua Nei Ke Za Zhi 1989, 28:463-465. 508.
43. Pisani F., Petrucci M.T., Giannarelli D., Bongarzoni V., Montanaro M., De Stefano V., et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res 2012, 31:17.
44. Liu J.R., Li J., Shang J.J., Zheng D., Gu J.L., Zou W.Y., Xu D.R. Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2013, 34:317-322.